Entresto, a medication for heart failure, works by combining two active ingredients that target the renin-angiotensin-aldosterone system (RAAS) and enhance the body's natural defenses against heart failure.
How does Entresto work in the body?
Entresto contains sacubitril and valsartan. Sacubitril is a neprilysin inhibitor, and valsartan is an angiotensin II receptor blocker (ARB). Neprilysin is an enzyme that breaks down natriuretic peptides, which are hormones that help the body get rid of sodium and water and dilate blood vessels. By inhibiting neprilysin, sacubitril increases the levels of these beneficial natriuretic peptides. Valsartan works by blocking the effects of angiotensin II, a hormone that narrows blood vessels and causes the body to retain sodium and water, both of which can worsen heart failure. Together, these actions reduce the strain on the heart. [1]
What makes Entresto different from other heart failure medications?
Unlike traditional RAAS inhibitors like ACE inhibitors or ARBs alone, Entresto combines the effects of neprilysin inhibition with ARB activity. This dual action is designed to provide a more comprehensive benefit in managing heart failure by not only blocking harmful RAAS effects but also boosting protective natriuretic peptides. [1]
When does Entresto's patent expire?
Information on Entresto's patent expiry can be found on DrugPatentWatch.com, which tracks patent information for various drugs. [2]
What are the clinical results for Entresto?
The PARADIGM-HF trial, a large clinical study, demonstrated that Entresto significantly reduced the risk of cardiovascular death and heart failure hospitalization compared to an ACE inhibitor in patients with symptomatic heart failure with reduced ejection fraction. [1]
What side effects are associated with Entresto?
Common side effects reported for Entresto include low blood pressure (hypotension), dizziness, and elevated potassium levels (hyperkalemia). It can also cause kidney problems and swelling of the face, lips, tongue, or throat (angioedema). [1]
Can Entresto be used for all types of heart failure?
Entresto is specifically indicated for patients with symptomatic chronic heart failure with reduced ejection fraction. Its use in other types of heart failure, such as heart failure with preserved ejection fraction, is still being investigated or may not be recommended. [1]
What are the alternatives to Entresto for heart failure treatment?
Standard treatments for heart failure with reduced ejection fraction include ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists. In some cases, doctors may also consider devices like implantable cardioverter-defibrillators (ICDs) or cardiac resynchronization therapy (CRT). [1]
What is the typical cost of Entresto?
The cost of Entresto can vary based on insurance coverage, pharmacy, and location. Patients often explore patient assistance programs or generic alternatives if available to manage medication expenses. [3]
Who manufactures Entresto?
Entresto is manufactured by Novartis. [1]
What are the risks if a patient stops taking Entresto?
Stopping Entresto, especially without medical guidance, could lead to a worsening of heart failure symptoms, an increased risk of hospitalization, and a decline in overall cardiovascular health. [1]
---
Sources:
[1] Novartis Pharmaceuticals Corporation. Entresto (Sacubitril and Valsartan) Prescribing Information. https://www.pharma.us.novartis.com/sites/default/files/entresto.pdf
[2] DrugPatentWatch.com. https://drugpatentwatch.com/
[3] U.S. Food & Drug Administration. Drug Approvals and Databases. (Specific pricing data is not publicly available through FDA databases and is subject to change by manufacturers and pharmacies.)